1. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS, Yariswamy M, Kemparaju K, Girish KS. N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine. Free Radic Res. 2013 May;47(5):357-67.
  2. Wall, G.M., 2020. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylcysteine amide (NACA) or (2R,2R)-3,3-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) US Patent 11766413
  3. Shen J, Yang X, Dong A, Petters RM, Peng YW, Wong F, Campochiaro PA. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol. 2005 Jun;203(3):457-64.
  4. Komeima K, Rogers BS, Lu L, Campochiaro PA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci USA 2006; 103: 11300-11305.
  5. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007; 213:809-815.
  6. Tuson M, Garanto A, Gonzalez-Duarte R, Marfany G. Over-expression of CERKL, a gene responsible for retinitis pigmentosa in humans, protects cells from apoptosis induced by oxidative stress. Molec Vis [serial online] 2009; 15:168-180.
  7. Usui S, Komeima K, Lee SY, et al. Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther 2009a; 17(5):778-786.
  8. Usui S, Overson BC, Lee SY, et al. NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem 2009b; 110: 1028-1037.
  9. Campochiaro PA, Mir TA. The mechanism of cone cell death in Retinitis Pigmentosa. Prog Retin Eye Res. 2018 Jan;62:24-37.
  10. Campochiaro PA, Strauss R, Lu L, Hafiz G, Wolfson Y, Shah SM, Sophie R, Mir TA and Scholl HP. Is there excess oxidative stress and damage in eyes of patients with retinitis pigmentosa? Antioxid Redox Signal. 2015 Sep 1; 23(7): 643-648.
  11. Carey JW, Pinarci EY, Penugonda S, Karacal H, Ercal N. In vivo inhibition of l-buthionine-(S,R)-sulfoximine-induced cataracts by a novel antioxidant, N-acetylcysteine amide. Free Radic Biol Med. 2011;50(6): 722-729.
  12. Tobwala S, Pinarci E, Maddirala Y, Ercal N. N-acetylcysteine amide protects against dexamethasone-induced cataract related changes in cultured rat lenses. Advances in Biological Chemistry. 2014:4, 26-34.
  13. Maddirala Y. Effects of N-acetylcysteine amide in preventing/treating cataracts. Doctoral Dissertation, Missouri University of Science and Technology, 2015. Effects of n-acetylcysteine amide in preventing/treating cataracts (mst.edu)
  14. Maddirala Y, Tobwala S, Karacal H, Ercal N. Prevention and reversal of selenite-induced cataracts by N-acetylcysteine amide in Wistar rats. BMC Ophthalmol. 2017 Apr 26;17(1):54.
  15. Martis RM, Grey AC, Wu H, Wall GM, Donaldson PJ, Lim JC. N-Acetylcysteine amide (NACA) and diNACA inhibit H2O2-induced cataract formation ex vivo in pig and rat lenses. Exp Eye Res. 2023 Sep;234:109610. Epub 2023 Aug 1. PMID: 37536438
  16. "Age Related Macular Regeneration", FFB website
  17. Schimel AM, Abraham L, Cox D, Sene A, Kraus C, Dace DS, Ercal N, Apte RS. N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation. Am J Pathol. 2011 May;178(5):2032-43. Epub 2011 Mar 31. PMID: 21457933; PMCID: PMC3081196.
  18. Wood JPM, Chidlow G, Wall GM, Casson RJ. N-acetylcysteine amide and di- N-acetylcysteine amide protect retinal cells in culture via an antioxidant action. Exp Eye Res. 2024 Nov;248:110074. Epub 2024 Sep 7. PMID: 39251120
  19. Vaisbich MH, Guimaraes LPDF, Shimizu MHM, Seguro AC. Oxidative Stress in cystinosis patients. Nephron Extra 2011;1:73-77
  20. Guimaraes LPDF, Seguro AC, Shimizu MHM, et al. N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis. Pediatr Nephrol. 2014; 29:1097-1102.
  21. Hector E, Cairns D, Wall GM. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis. Orphanet J Rare Dis. 2022. In press.
  22. March ME, Gutierrez-Uzquiza A, Snorradottir AO, Matsuoka LS, Balvis NF, Gestsson T, Nguyen K, Sleiman PMA, Kao C, Isaksson HJ, Bragason BT, Olafsson E, Palsdottir A, Hakonarson H. NAC blocks Cystatin C amyloid complex aggregation in a cell system and in skin of HCCAA patients. Nat Commun. 2021;Mar 23;12(1):1827.
  23. He R, Zheng W, Ginman T, Ottosson H, Norgren S, Zhao Y, Hassan M. Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. Eur J Pharm Sci.2020; Feb 15;143:105158.
  24. Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017;Dec25;23(1):40.
  25. Chung, HL, Wangler MF, Marcogliese PC, Jo J, Ravenscroft TA, Zuo Z, Duraine L, Sadeghzadeh S, Li-Kroeger D, Schmidt RE, Pestronk A, Rosenfeld JA, Burrage L, Herndon MJ, Chen S, Members of Undiagnosed Diseases Network, Shillington A, Vawter-Lee M, Hopkin R, Rodriguez-Smith J, Bellen HJ. Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Neuron 2020;106(4), 589-606.e6.
  26. Griffin EN and Ackerman SL. Lipid Metabolism and Axon Degeneration: An ACOX1 Balancing Act. Neuron. 2020;106(4), 551-553.
  27. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132-141.
  28. "Usher Syndrome", NIDCD website
  29. Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs. Clin Ophthalmol. 2022 Jun 20;16:1993-2010. doi: 10.2147/OPTH.S365486. PMID: 35757022; PMCID: PMC9232096
  30. Lee SY, Usui S, Zafar A-B, Oveson BD, Jo, Y-J, Lu L, Masoudi S, Campochiaro PA. N-AcetyIcysteine promotes long-term survival of cones in a model of retinitis pigimentosa. J Cell Physiol 2011; 226; 1843-1849.
  31. Dong A, Stevens R, Hackett S, Campochiaro PA. Compared with N-acetylcysteine (NAC), N-Acetylcysteine Amide (NACA) Provides Increased Protection of Cone Function in a Model of Retinitis Pigmentosa. Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1736.
  32. Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, Lu L, Wall GM, Singh MS, Kong X. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest. 2020 Mar 2;130(3):1527-1541.
  33. Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem. 2004 Jun;89(5):1241-51. doi: 10.1111/j.1471-4159.2004.02428.x. PMID: 15147517
  34. Grinberg L, Fibach E, Amer J, Atlas D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress.Free Radic Biol Med. 2005 Jan 1;38(1):136-45.
  35. Babizhayev MA, Deyev AI, Yermakova VN, et al. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther. 2006;1:91-116.
  36. Martis RM, Grey AC, Wu H, Wall GM, Donaldson PJ, Lim JC. N-Acetylcysteine amide (NACA) and diNACA inhibit H2O2-induced cataract formation ex vivo in pig and rat lenses. Exp Eye Res. 2023 Sep;234:109610. doi: 10.1016/j.exer.2023.109610. Epub 2023 Aug 1. PMID: 37536438
  37. Ariceta G, Giordano V, Santos F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatr Nephrol. 2019;34(4):571-578. doi:10.1007/s00467-017-3856-4.
  38. Cairns D, Anderson R, Coulthard M, Terry J. Cystinosis and its treatment. Pharmaceutical Journal. 2002;269:615-16
  39. Touchman JW, Anikster Y, Dietrich NL, Braden Maduro VV, McDowell G, Shotelersuk V, Bouffard GG, Beckstrom-Sternberg SM, Gahl WA, Green ED. The genomic region encompassing the nephropathic cystinosis gene (CTNS): Complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome research. 2000; 10(2):165-173.
  40. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. NE J Med, 1987; 316(16):971-977.